We no longer need to consider if laparoendoscopic single-site surgery is safe and effective-with the caveat of experienced hands-but we do need to examine in whom the cosmetic advantages of LESS merit the added surgical complexity.
The concern is that performing surgery through a 2- to 4-cm incision might risk poor surgical outcomes. Numerous articles suggest that this is not the case, at least when performed by very experienced surgeons in carefully selected patients. As such, the debate about LESS versus multi-port laparoscopy needs to evolve. We no longer need to consider if LESS is safe and effective-with the caveat of experienced hands-but we do need to examine in whom the cosmetic advantages of LESS merit the added surgical complexity.
In this issue of Urology Times, an important contribution from the University of Texas Southwestern Medical Center and the University of Iowa informs this debate. These urologists have been leaders in developing LESS, and now they are helping to clarify its role. Using a questionnaire ranking various surgical outcomes, these investigators found that surgical scarring was low on the list of patients' priorities.
We need to go even further than this, though. It would be incorrect to assume that LESS always provides a better cosmetic outcome than multi-port laparoscopy, especially if the latter is modified using smaller ports that are strategically placed. There are validated questionnaires that can be used to compare scars and body image perception, and we should use these to truly determine which procedures provide the cosmetic results we think we are providing.
Dr. Wolf, a member of the Urology Times Editorial Council, is professor of urology at the University of Michigan, Ann Arbor.
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.